[go: up one dir, main page]

WO2019035057A3 - Exosomes for target specific delivery and methods for preparing and delivering the same - Google Patents

Exosomes for target specific delivery and methods for preparing and delivering the same Download PDF

Info

Publication number
WO2019035057A3
WO2019035057A3 PCT/IB2018/056200 IB2018056200W WO2019035057A3 WO 2019035057 A3 WO2019035057 A3 WO 2019035057A3 IB 2018056200 W IB2018056200 W IB 2018056200W WO 2019035057 A3 WO2019035057 A3 WO 2019035057A3
Authority
WO
WIPO (PCT)
Prior art keywords
exosome
preparing
exosomes
delivering
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/056200
Other languages
French (fr)
Other versions
WO2019035057A2 (en
Inventor
Chulhee Choi
Nambin YIM
Hojun CHOI
Kyungsun CHOI
Seung-Wook RYU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilias Biologics Inc
Original Assignee
Cellex Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2019035057(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA3073162A priority Critical patent/CA3073162C/en
Priority to JP2020530742A priority patent/JP7224352B2/en
Priority to US16/639,740 priority patent/US20200206360A1/en
Priority to EP18846900.1A priority patent/EP3668552A4/en
Priority to CN201880067512.6A priority patent/CN111629761B/en
Priority to AU2018316803A priority patent/AU2018316803B2/en
Application filed by Cellex Life Sciences Inc filed Critical Cellex Life Sciences Inc
Publication of WO2019035057A2 publication Critical patent/WO2019035057A2/en
Publication of WO2019035057A3 publication Critical patent/WO2019035057A3/en
Priority to IL272684A priority patent/IL272684B2/en
Anticipated expiration legal-status Critical
Priority to AU2021250906A priority patent/AU2021250906B2/en
Priority to US18/412,403 priority patent/US12133879B2/en
Priority to US18/887,997 priority patent/US20250009845A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de production d'un exosome qui transfère une substance active spécifiquement à une cible, et l'exosome produit par ledit procédé; un procédé d'administration de la substance active au tissu cible à l'aide de l'exosome; une composition pharmaceutique pour l'administration de la substance active comprenant l'exosome en tant que principe actif; et une composition pour préparer l'exosome comprenant un vecteur d'expression où le peptide cible est inséré dans une partie extracellulaire d'une protéine transmembranaire.The present invention relates to a method of producing an exosome that transfers an active substance specifically to a target, and the exosome produced by said method; a method of administering the active substance to the target tissue using the exosome; a pharmaceutical composition for the administration of the active substance comprising the exosome as an active ingredient; and a composition for preparing the exosome comprising an expression vector wherein the target peptide is inserted into an extracellular portion of a transmembrane protein.

PCT/IB2018/056200 2015-05-04 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same Ceased WO2019035057A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA3073162A CA3073162C (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
JP2020530742A JP7224352B2 (en) 2017-08-17 2018-08-16 Exosomes for target-specific delivery and methods for producing and delivering the same
US16/639,740 US20200206360A1 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
EP18846900.1A EP3668552A4 (en) 2017-08-17 2018-08-16 TARGET ADMINISTRATION EXOSOMES AND METHOD OF PREPARATION AND ADMINISTRATION
CN201880067512.6A CN111629761B (en) 2017-08-17 2018-08-16 Exosomes for target-specific delivery and methods for preparing and delivering the exosomes
AU2018316803A AU2018316803B2 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
IL272684A IL272684B2 (en) 2017-08-17 2020-02-16 Exosomes for target specific delivery and methods for preparing and delivering the same
AU2021250906A AU2021250906B2 (en) 2017-08-17 2021-10-13 Exosomes for target specific delivery and methods for preparing and delivering the same
US18/412,403 US12133879B2 (en) 2015-05-04 2024-01-12 Exosomes for target specific delivery and methods for preparing and delivering the same
US18/887,997 US20250009845A1 (en) 2015-05-04 2024-09-17 Exosomes for target specific delivery and methods for preparing and delivering the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170104171 2017-08-17
KR10-2017-0104171 2017-08-17
US201862659816P 2018-04-19 2018-04-19
US62/659,816 2018-04-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004750 Continuation-In-Part WO2016178532A1 (en) 2015-05-04 2016-05-04 Production method for exosome comprising target protein, and method for transferring target protein into cytoplasm by using exosome produced by means of the production method

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/639,740 A-371-Of-International US20200206360A1 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
US18/412,403 Continuation-In-Part US12133879B2 (en) 2015-05-04 2024-01-12 Exosomes for target specific delivery and methods for preparing and delivering the same

Publications (2)

Publication Number Publication Date
WO2019035057A2 WO2019035057A2 (en) 2019-02-21
WO2019035057A3 true WO2019035057A3 (en) 2019-04-25

Family

ID=65361814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/056200 Ceased WO2019035057A2 (en) 2015-05-04 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same

Country Status (2)

Country Link
KR (1) KR102100420B1 (en)
WO (1) WO2019035057A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102125567B1 (en) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 Large-Scale Production of Plant Derived Exosomes
US20210093567A1 (en) * 2019-08-06 2021-04-01 Ohio State Innovation Foundation Therapeutic extracellular vesicles
WO2021045501A1 (en) * 2019-09-02 2021-03-11 경북대학교 산학협력단 Composition for preventing or treating cancer, containing il-2 surface expression-extracellular vesicles as active ingredient
JP2023512562A (en) * 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド artificial synapse
US20230126199A1 (en) * 2020-02-28 2023-04-27 National University Corporation Kanazawa University Immunoregulatory method, nucleic acid composition for immunoregulation and use thereof
EP4117717A1 (en) * 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
CN113679850B (en) * 2020-05-19 2023-05-19 首都医科大学附属北京天坛医院 A kind of exosome that is targetedly modified and loaded with drugs and its preparation method and application
KR102341138B1 (en) * 2020-05-31 2021-12-21 주식회사 엑소코바이오 Exosomes comprising exosomal membrane protein variant and manufacturing method thereof
KR102699872B1 (en) * 2021-04-29 2024-08-29 주식회사 서지넥스 Colorectal cancer specific targeting exosome composition as a drug anticancer delivery and use thereof
KR102699871B1 (en) * 2021-04-29 2024-08-29 주식회사 서지넥스 Hepatocellular carcinoma specific targeting exosome composition as a drug anticancer delivery and use thereof
KR102620197B1 (en) * 2021-04-30 2024-01-02 가톨릭대학교 산학협력단 Colorectal cancer specific targeting exosome composition as a drug anticancer delivery and use thereof
KR102632530B1 (en) * 2021-05-24 2024-02-02 가톨릭대학교 산학협력단 Stomach cancer specific targeting exosome composition as a drug anticancer delivery and use thereof
KR20230013009A (en) 2021-07-16 2023-01-26 서울대학교산학협력단 Extracellular endoplasmic reticulum and manufacturing method thereof
KR20250040552A (en) * 2023-09-14 2025-03-24 주식회사 엑소스템텍 Therapeutic protein delivery specific for brain using exosomes comprising protein for treating degenerative brain diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US20160137716A1 (en) * 2013-04-12 2016-05-19 Samir El Andaloussi Therapeutic delivery vesicles
KR20160130937A (en) * 2015-05-04 2016-11-15 한국과학기술원 Process for preparing exosome loading target protein and method for loading target protein to cytosol by using exosome prepared thereby

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160137716A1 (en) * 2013-04-12 2016-05-19 Samir El Andaloussi Therapeutic delivery vesicles
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
KR20160130937A (en) * 2015-05-04 2016-11-15 한국과학기술원 Process for preparing exosome loading target protein and method for loading target protein to cytosol by using exosome prepared thereby

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HA, DINH ET AL.: "Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges", ACTA PHARMACEUTICA SINICA B, vol. 6, no. 4, 2016, pages 287 - 296, XP055303644, DOI: doi:10.1016/j.apsb.2016.02.001 *
KOTMAKCI, MUSTAFA ET AL.: "Extracellular vesicles as natural nanosized delivery systems for small-molecule drugs and genetic material: steps towards the future nanomedicines", JOURNAL OF PHARMACY & PHARMACEUTICAL SCIENCES, vol. 18, no. 3, 2015, pages 396 - 413, XP055594743 *

Also Published As

Publication number Publication date
KR102100420B1 (en) 2020-04-13
KR20190019872A (en) 2019-02-27
WO2019035057A2 (en) 2019-02-21
KR102100420B9 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
WO2019035057A3 (en) Exosomes for target specific delivery and methods for preparing and delivering the same
EA201991299A1 (en) PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR DELIVERY OF OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENTS
MX2021000196A (en) Milk vesicles for use in delivering biological agents.
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
SG11201810270SA (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
PH12021551635A1 (en) Hexone glucokinase inhibitor and use thereof
CA3016457A1 (en) Sting activating nanovaccine for immunotherapy
MX2017012506A (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYE DISEASES CONTAINING, AS ACTIVE INGREDIENT, A FUSION PROTEIN IN WHICH THE PEPTIDE THAT PENETRATES THE TISSUE AND THE PREPARATION OF THE ANTI-ASCULAR ENDOTELIAL GROWTH FACTOR IS FUSED.
Wang et al. Cutting edge: the heat shock protein gp96 activates inflammasome-signaling platforms in APCs
CY1118826T1 (en) PROCEDURE FOR CONSTRUCTION OF A GLATIRAMER ACETATE CONTAINER
JP2016510729A (en) Disulfide compounds for drug delivery
BR112018012641A2 (en) drug carrier cell penetration molecule, methods for facilitating incorporation of a biologically active compound (bac) into a cell, for improving the bioavailability of a drug or bac, for introducing a drug or bac at a site, and for altering expression of an endogenous or exogenous gene, and, composition.
KR102144323B1 (en) Pharmaceutical composition comprising glutathione disulfide and glutathione disulfide S-oxide
Liu et al. Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-κB-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
MX2021009526A (en) Drug delivery compositions for ocular administration of therapeutics and methods of use thereof.
MX2021012994A (en) HETEROLOGICAL ADMINISTRATION OF TAU VACCINES.
Busnardo et al. Ionotropic glutamate receptors in hypothalamic paraventricular and supraoptic nuclei mediate vasopressin and oxytocin release in unanesthetized rats
JOP20210185A1 (en) Haloallylamine compounds and application thereof
IL307997A (en) Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases
Mameli et al. Bromelain: An overview of applications in medicine and dentistry
MA53189A1 (en) Pharmaceutical composition intended for the treatment of aplastic anemia
MX2020002247A (en) LONG-TERM PALMITIC ACID CONJUGATE DERIVATIVE OF GNRH AND PHARMACEUTICAL COMPOSITION CONTAINING IT.
EP3496737A1 (en) Apom-fc fusion proteins, complexes thereof with sphingosine l-phosphate (sip), and methods for treating vascular and non-vascular diseases
CN103980353A (en) Hydrophobin and medicinal preparation containing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846900

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3073162

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020530742

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018846900

Country of ref document: EP

Effective date: 20200317

ENP Entry into the national phase

Ref document number: 2018316803

Country of ref document: AU

Date of ref document: 20180816

Kind code of ref document: A